Related Experiment Videos
EEG abnormalities during treatment with typical and atypical antipsychotics
Franca Centorrino1, Bruce H Price, Margaret Tuttle
1Bipolar and Psychotic Disorder Program, McLean Hospital, MA 02478, USA. centorf@mcleanpo.mclean.org
The American Journal of Psychiatry
|January 5, 2002
Summary
EEG abnormality risk varies significantly among antipsychotic drugs, with clozapine and olanzapine posing the highest risk. Quetiapine showed no associated risk, highlighting the need for careful drug selection in psychiatric treatment.
Area of Science:
- Neuroscience
- Psychopharmacology
- Clinical Neurology
Background:
- Clozapine is known to cause EEG abnormalities and seizures.
- Limited data exists on the electroencephalographic (EEG) effects of newer antipsychotic medications.
- Understanding these effects is crucial for patient safety and treatment optimization.
Purpose of the Study:
- To investigate and compare the risk of EEG abnormalities across various antipsychotic drugs.
- To identify clinical factors associated with increased EEG abnormality risk.
Main Methods:
- EEG recordings were analyzed from 323 hospitalized psychiatric patients (293 on antipsychotics, 30 controls).
- Recordings were blindly graded for EEG abnormalities.
- Multivariate logistic regression analyzed associations between drug type, dose, and clinical factors with EEG abnormalities.
Main Results:
- EEG abnormalities were observed in 19.1% of patients treated with antipsychotics versus 13.3% of controls.
- Risk varied significantly by drug: clozapine (47.1%), olanzapine (38.5%), risperidone (28.0%), typical neuroleptics (14.5%), and quetiapine (0.0%).
- Hypertension, atypical antipsychotic use, bipolar diagnosis, and older age were significant risk factors; benzodiazepine co-treatment reduced risk.
Conclusions:
- The risk of EEG abnormalities differs substantially among antipsychotic medications.
- Clozapine and olanzapine present a high risk, while quetiapine shows minimal risk.
- Comorbid hypertension, bipolar disorder, and advanced age are associated with increased risk, independent of drug dosage or clinical response.